NovaBay Pharmaceuticals (NYSE:NBY) Receiving Somewhat Positive Media Coverage, Analysis Shows
Press coverage about NovaBay Pharmaceuticals (NYSE:NBY) has been trending somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. NovaBay Pharmaceuticals earned a coverage optimism score of 0.03 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 45.6357698251743 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:
- NovaBay Pharmaceuticals, Inc. (NYSE:NBY) Downgraded by Zacks Investment Research (americanbankingnews.com)
- NovaBay Pharmaceuticals to Hold 2017 Second … (ih.advfn.com)
- Analysts Anticipate NovaBay Pharmaceuticals, Inc. (NBY) Will Post Quarterly Sales of $4.57 Million (americanbankingnews.com)
- Revance Therapeutics Expands Leadership Team, Appointing Todd Zavodnick Chief Commercial Officer and President, Aesthetics & Therapeutics (businesswire.com)
NovaBay Pharmaceuticals (NYSE NBY) traded down 2.4340% during mid-day trading on Tuesday, hitting $4.5856. 11,208 shares of the stock traded hands. NovaBay Pharmaceuticals has a 12-month low of $2.25 and a 12-month high of $5.29. The firm’s 50-day moving average is $3.83 and its 200-day moving average is $3.59. The company’s market cap is $70.20 million.
Several analysts recently issued reports on NBY shares. Zacks Investment Research cut shares of NovaBay Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, April 11th. Maxim Group reaffirmed a “hold” rating on shares of NovaBay Pharmaceuticals in a research note on Saturday, May 13th. Finally, Roth Capital started coverage on shares of NovaBay Pharmaceuticals in a research note on Monday, June 5th. They set a “buy” rating and a $5.50 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $7.00.
About NovaBay Pharmaceuticals
NovaBay Pharmaceuticals, Inc, formerly NovaCal Pharmaceuticals, Inc, is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox.
Receive News & Ratings for NovaBay Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.